Published in J Clin Endocrinol Metab on August 09, 2005
Prosurvival effect of DHCR24/Seladin-1 in acute and chronic responses to oxidative stress. Mol Cell Biol (2007) 1.03
Down-regulation of seladin-1 increases BACE1 levels and activity through enhanced GGA3 depletion during apoptosis. J Biol Chem (2009) 0.91
Role of oxidative stress in hepatocarcinogenesis induced by hepatitis C virus. Int J Mol Sci (2012) 0.88
Somatostatin and opioid receptors do not regulate proliferation or apoptosis of the human multiple myeloma U266 cells. J Exp Clin Cancer Res (2009) 0.81
Promoter analysis of the DHCR24 (3β-hydroxysterol Δ(24)-reductase) gene: characterization of SREBP (sterol-regulatory-element-binding protein)-mediated activation. Biosci Rep (2012) 0.80
3β-hydroxysterol δ24-reductase on the surface of hepatitis C virus-related hepatocellular carcinoma cells can be a target for molecular targeting therapy. PLoS One (2015) 0.80
Seladin-1 expression is regulated by promoter methylation in adrenal cancer. BMC Cancer (2010) 0.78
Involvement of Seladin-1 in goniothalamin-induced apoptosis in urinary bladder cancer cells. BMC Complement Altern Med (2014) 0.77
Antiproliferative effects of somatostatin analogs in endocrine tumours. F1000 Med Rep (2009) 0.76
Individualized markers optimize class prediction of microarray data. BMC Bioinformatics (2006) 0.76
Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med (2014) 4.00
Isolation and characterization of multipotent progenitor cells from the Bowman's capsule of adult human kidneys. J Am Soc Nephrol (2006) 3.95
Regeneration of glomerular podocytes by human renal progenitors. J Am Soc Nephrol (2008) 3.80
An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med (2003) 2.91
Regenerative potential of embryonic renal multipotent progenitors in acute renal failure. J Am Soc Nephrol (2007) 2.42
Essential but differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal progenitor cells. J Exp Med (2008) 2.25
Metalloproteinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI. Int J Cardiol (2007) 2.05
CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol (2004) 1.77
Stability of BAT26 in tumours of hereditary nonpolyposis colorectal cancer patients with MSH2 intragenic deletion. Eur J Hum Genet (2006) 1.71
High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol (2011) 1.69
Hypogonadotropic hypogonadism as a presenting feature of late-onset X-linked adrenal hypoplasia congenita. J Clin Endocrinol Metab (2002) 1.68
PTX3 plays a key role in the organization of the cumulus oophorus extracellular matrix and in in vivo fertilization. Development (2004) 1.68
PRKAR1A and PDE4D mutations cause acrodysostosis but two distinct syndromes with or without GPCR-signaling hormone resistance. J Clin Endocrinol Metab (2012) 1.68
Growth hormone-releasing hormone resistance in pseudohypoparathyroidism type ia: new evidence for imprinting of the Gs alpha gene. J Clin Endocrinol Metab (2003) 1.67
The gsalpha gene: predominant maternal origin of transcription in human thyroid gland and gonads. J Clin Endocrinol Metab (2002) 1.67
PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate (2013) 1.67
Pseudohypoparathyroidism and GNAS epigenetic defects: clinical evaluation of albright hereditary osteodystrophy and molecular analysis in 40 patients. J Clin Endocrinol Metab (2010) 1.53
Circulating levels of ghrelin in human fetuses. Eur J Endocrinol (2003) 1.52
Ghrelin and adiponectin in patients with Cushing's disease before and after successful transsphenoidal surgery. Clin Endocrinol (Oxf) (2005) 1.51
Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med (2014) 1.49
Seladin-1 is a fundamental mediator of the neuroprotective effects of estrogen in human neuroblast long-term cell cultures. Endocrinology (2008) 1.46
Role of chemokines in endocrine autoimmune diseases. Endocr Rev (2007) 1.43
Influence of the d3GH receptor polymorphism on the metabolic and biochemical phenotype of GH-deficient adults at baseline and during short- and long-term recombinant human GH replacement therapy. Eur J Endocrinol (2010) 1.42
A case of brain abscess by Eikenella corrodens in a HIV-positive patient. Ann Ital Med Int (2003) 1.39
CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production. J Allergy Clin Immunol (2005) 1.35
Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Anticancer Drugs (2008) 1.28
Maternal and foetal resistin and adiponectin concentrations in normal and complicated pregnancies. Clin Endocrinol (Oxf) (2007) 1.26
Functional differences in visceral and subcutaneous fat pads originate from differences in the adipose stem cell. PLoS One (2012) 1.25
Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab (2010) 1.24
An alternate translation initiation site circumvents an amino-terminal DAX1 nonsense mutation leading to a mild form of X-linked adrenal hypoplasia congenita. J Clin Endocrinol Metab (2003) 1.23
Human bladder as a novel target for vitamin D receptor ligands. J Clin Endocrinol Metab (2004) 1.22
Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J Endocrinol (2011) 1.16
Mutations in the Gs alpha gene causing hormone resistance. Best Pract Res Clin Endocrinol Metab (2006) 1.15
Biallelic expression of the Gsalpha gene in human bone and adipose tissue. J Clin Endocrinol Metab (2004) 1.14
Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol (2006) 1.14
Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J Endocrinol (2012) 1.13
Characterization of human adult stem-cell populations isolated from visceral and subcutaneous adipose tissue. FASEB J (2009) 1.13
High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab (2004) 1.11
Genetic variants in miR-146a, miR-149, miR-196a2, miR-499 and their influence on relative expression in lung cancers. Clin Chem Lab Med (2011) 1.09
Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate (2012) 1.07
Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab (2005) 1.07
Genetic and epigenetic factors in regulation of microRNA in colorectal cancers. Methods (2012) 1.07
Genetic insights into familial tumors of the nervous system. Am J Med Genet C Semin Med Genet (2004) 1.06
Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease. Am J Pathol (2002) 1.06
Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells. Hepatology (2008) 1.06
Plasma cell granuloma--an enigmatic lesion: description of an extensive intracranial case and review of the literature. Arch Pathol Lab Med (2003) 1.04
Prosurvival effect of DHCR24/Seladin-1 in acute and chronic responses to oxidative stress. Mol Cell Biol (2007) 1.03
Conservative surgical therapy for leydig cell tumor. J Urol (2007) 1.02
High CXCL10 expression in rejected kidneys and predictive role of pretransplant serum CXCL10 for acute rejection and chronic allograft nephropathy. Transplantation (2005) 1.02
Mechanisms of disease: Mutations of G proteins and G-protein-coupled receptors in endocrine diseases. Nat Clin Pract Endocrinol Metab (2006) 1.01
Genetic analysis and evaluation of resistance to thyrotropin and growth hormone-releasing hormone in pseudohypoparathyroidism type Ib. J Clin Endocrinol Metab (2007) 1.01
Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. Eur J Endocrinol (2006) 1.01
Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. Clin Endocrinol (Oxf) (2006) 0.99
Proliferation of transformed somatotroph cells related to low or absent expression of protein kinase a regulatory subunit 1A protein. Cancer Res (2004) 0.99
IP-10 and Mig production by glomerular cells in human proliferative glomerulonephritis and regulation by nitric oxide. J Am Soc Nephrol (2002) 0.98
Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome. J Steroid Biochem Mol Biol (2012) 0.98
Cell-specific regulation of PTX3 by glucocorticoid hormones in hematopoietic and nonhematopoietic cells. J Biol Chem (2008) 0.97
The CXCR4/CXCL12 axis in endometrial cancer. Clin Exp Metastasis (2009) 0.97
Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J Clin Endocrinol Metab (2004) 0.97
Increase of CXC chemokine CXCL10 and CC chemokine CCL2 serum levels in normal ageing. Cytokine (2006) 0.96
The treatment of adults with medulloblastoma: a prospective study. Int J Radiat Oncol Biol Phys (2003) 0.96
Peroxisome proliferator-activated receptor gamma (PPARgamma): Is the genomic activity the only answer? Steroids (2009) 0.96
cAMP in the pituitary: an old messenger for multiple signals. J Mol Endocrinol (2013) 0.96
Molecular genetic alterations and clinical features in early-onset colorectal carcinomas and their role for the recognition of hereditary cancer syndromes. Am J Gastroenterol (2005) 0.95
High pretransplant serum levels of CXCL10/IP-10 are related to increased risk of renal allograft failure. Am J Transplant (2004) 0.95
The microRNA cluster C19MC is deregulated in parathyroid tumours. J Mol Endocrinol (2012) 0.95
Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling. PPAR Res (2008) 0.95
Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity. J Bone Miner Res (2009) 0.95
Androgen receptor regulation of the seladin-1/DHCR24 gene: altered expression in prostate cancer. Lab Invest (2008) 0.94
Resistance to growth hormone releasing hormone and gonadotropins in Albright's hereditary osteodystrophy. J Pediatr Endocrinol Metab (2006) 0.94
PF-4/CXCL4 and CXCL4L1 exhibit distinct subcellular localization and a differentially regulated mechanism of secretion. Blood (2007) 0.94
Analysis of gene expression profiles reveals novel correlations with the clinical course of colorectal cancer. Oncol Res (2007) 0.94
Inflammatory response in human skeletal muscle cells: CXCL10 as a potential therapeutic target. Eur J Cell Biol (2011) 0.94
Estrogen and selective estrogen receptor modulators exert neuroprotective effects and stimulate the expression of selective Alzheimer's disease indicator-1, a recently discovered antiapoptotic gene, in human neuroblast long-term cell cultures. J Clin Endocrinol Metab (2004) 0.93
Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria. J Clin Endocrinol Metab (2004) 0.93
A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-alpha and interferon-gamma inflammatory effects in human endothelial cells. Arterioscler Thromb Vasc Biol (2008) 0.93
Brain networks underlying the clinical effects of long-term subthalamic stimulation for Parkinson's disease: a 4-year follow-up study with rCBF SPECT. J Nucl Med (2005) 0.92
Autosomal dominant pseudohypoparathyroidism type Ib: a novel inherited deletion ablating STX16 causes loss of imprinting at the A/B DMR. J Clin Endocrinol Metab (2014) 0.92
Neuronal differentiation of human mesenchymal stem cells: changes in the expression of the Alzheimer's disease-related gene seladin-1. Exp Cell Res (2006) 0.92